Jupiter Neurosciences Selected as B2i Digital Featured Company

Clinical-Stage Pharmaceutical Company Advancing Phase IIa Parkinson's Trial

Published on Feb. 13, 2026

Got story updates? Submit your updates here. ›

Jupiter Neurosciences, Inc. (NASDAQ:JUNS), a clinical-stage pharmaceutical company, has been selected as a B2i Digital Featured Company. The company is advancing a therapeutic pipeline targeting neuroinflammation and central nervous system (CNS) disorders, led by an FDA-cleared Phase IIa clinical trial in Parkinson's disease. Alongside its clinical program, Jupiter is expanding a consumer brand powered by its proprietary JOTROL™ enhanced resveratrol formulation, creating a dual-path strategy that combines clinical development with emerging commercial revenue pathways.

Why it matters

Jupiter Neurosciences' dual-path strategy of advancing a therapeutic pipeline while also building a consumer product line sets it apart in the CNS sector. The company's progress in its Phase IIa Parkinson's trial and the expansion of its consumer brand powered by JOTROL™ demonstrate its ability to create value through both clinical development and commercial revenue streams.

The details

Jupiter Neurosciences is advancing a therapeutic pipeline targeting neuroinflammation and CNS disorders, including a Phase IIa clinical trial in Parkinson's disease. The company is also exploring additional indications, such as Alzheimer's disease, Friedreich's Ataxia, Mucopolysaccharidoses Type I, and MELAS, supported by research collaborations with leading academic institutions. Alongside its clinical program, Jupiter is expanding a consumer brand powered by its proprietary JOTROL™ enhanced resveratrol formulation, creating a differentiated operating model as key milestones advance.

  • Jupiter Neurosciences is currently conducting a Phase IIa clinical trial in Parkinson's disease.

The players

Jupiter Neurosciences, Inc.

A clinical-stage pharmaceutical company pursuing a dual-path strategy to address neuroinflammation and promote healthy aging.

David Shapiro

Chief Executive Officer of B2i Digital, Inc.

Christer Rosén

Founder, Chairman, and CEO of Jupiter Neurosciences.

Got photos? Submit your photos here. ›

What they’re saying

“Jupiter Neurosciences offers investors a differentiated opportunity within the CNS sector. With a Phase IIa Parkinson's trial underway and a consumer platform already in market, the company is advancing its pipeline while building potential revenue streams. We look forward to expanding their visibility across our investor network.”

— David Shapiro, Chief Executive Officer of B2i Digital, Inc.

“We believe we are entering an important inflection point. As our Parkinson's program progresses and our consumer products continue to scale, partnering with B2i Digital strengthens our ability to communicate our story to the broader capital markets.”

— Christer Rosén, Founder, Chairman, and CEO of Jupiter Neurosciences

The takeaway

Jupiter Neurosciences' dual-path strategy of advancing a therapeutic pipeline while also building a consumer product line demonstrates its ability to create value through both clinical development and commercial revenue streams, setting it apart in the CNS sector.